Gefitinib News and Research

RSS

Gefitinib is approved by the Food and Drug Administration (FDA) to treat locally advanced or metastatic non-small cell lung cancer (NSCLC) that has not gotten better after treatment with other chemotherapy. It is available only as part of a special program called the Iressa Access Program. Gefitinib is also being studied in the treatment of other types of cancer.

Gefitinib is an anilinoquinazoline with antineoplastic activity. Gefitinib inhibits the catalytic activity of numerous tyrosine kinases including the epidermal growth factor receptor (EGFR), which may result in inhibition of tyrosine kinase-dependent tumor growth. Specifically, this agent competes with the binding of ATP to the tyrosine kinase domain of EGFR, thereby inhibiting receptor autophosphorylation and resulting in inhibition of signal transduction. Gefitinib may also induce cell cycle arrest and inhibit angiogenesis.

Focusing on oncogenic driver mutations and resistance mechanisms in the treatment of NSCLC

Lung cancer is the leading cause of cancer-related death worldwide. Improved understanding of driver mutations of non-small cell lung cancer (NSCLC) has led to more biomarker-directed treatment for patients with advanced stages.

26 Mar 2024

$2.8 million awarded to translate research on how cancer cells evolve and compete into patient care

The National Institutes of Health recently awarded Cleveland Clinic's Jacob Scott, M.D., D.Phil., and collaborators $2.8 million to translate research on how cancer cells evolve and compete into patient care.

22 Aug 2023

Effect of mutations in cancer-driving genes across human cancers

Effect of mutations in cancer-driving genes across human cancers.

9 Aug 2023

Study reveals the underlying mechanism by which TKI cancer drugs cause inflammation

Tyrosine kinase inhibitors are a type of targeted cancer medicine that can attack specific types of cancer cells and prevent them from multiplying.

17 Mar 2023

Study provides better understanding of how therapeutic resistance develops in lung cancer

New Cleveland Clinic research has uncovered key information about cellular interaction between tumor cells and normal tissue, providing better understanding of how therapeutic resistance develops.

1 Jul 2022

Importance of Numb-associated kinases in SARS-CoV-2 infection

A new study posted to the bioRxiv* preprint server has focussed on assessing four members of the NAK family that are associated with SARS-CoV-2 infection. These kininases could act as a target for the development of effective COVID-19 therapeutics.

23 Mar 2022

New approach could be a useful tool in the fight against cancer drug resistance

Using a virus to purposely mutate genes that produce cancer-driving proteins could shed light on the resistance that inevitably develops to cancer drugs that target them, a new study led by UT Southwestern scientists suggests.

10 Aug 2021

Scientists discover new treatment target for osteoarthritis-like knee cartilage degeneration

There is currently no cure for osteoarthritis, but a group of scientists believe they've discovered a method through which a simple knee injection could potentially stop the disease's effects.

16 Jan 2021

Promising new antivirals target arboviruses and SARS-CoV-2: Nodosome inhibitors

A new study describes two promising small molecules that inhibit a host cell factor, called nucleotide binding oligomerization domain-containing protein 2 (NOD2), that inhibits the replication and spread of many arboviruses. This could lead to the development of broad-spectrum antivirals. The study's findings have been published on the preprint server bioRxiv*.

10 Nov 2020

Turning autoimmunity drugs into anti-cancer treatments

Professor Mark Cragg speaks to News-Medical about his research which involves turning autoimmunity drugs into anti-cancer treatments.

11 Jun 2020

AI could enhance prediction of treatment response among patients with non-small cell lung cancer

Artificial intelligence deep learning algorithms may predict response to systemic treatment for non-small cell lung cancer.

23 Mar 2020

AI may help predict tumor sensitivity to systemic cancer therapies

Using standard-of-care computed tomography scans in patients with advanced non-small cell lung cancer, researchers utilized artificial intelligence to train algorithms to predict tumor sensitivity to three systemic cancer therapies.

20 Mar 2020

Dacomitinib treatment for lung cancer increases overall survival but has more side effects

Since its approval in April 2019, dacomitinib has been available for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor activating mutations.

20 Aug 2019

Study: Cancer stem-like cells are maintained by MTHFD2 mitochondrial metabolic enzyme

An increase in the incidence and mortality rate of cancer has been noted worldwide, especially for lung cancer.

22 Feb 2019

Toxic effects of drugs in the lungs 'more widespread than thought'

A systematic review of research has revealed that the toxic effects on the lung of drugs commonly taken to treat a range of common conditions is much more widespread than thought.

29 Oct 2018

Study: Erlotinib improves progression-free survival in EGFR mutated NSCLC

Neoadjuvant erlotinib benefits selected epidermal growth factor receptor (EGFR)-mutated patients who undergo complete resection of stage IIIA-N2 stage non-small cell lung cancer(NSCLC), shows a randomized study comparing erlotinib with gemcitabine plus cisplatin as neoadjuvant treatment, presented at the ESMO 2018 Congress in Munich.

22 Oct 2018

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved VIZIMPRO [vih-ZIM-pro] (dacomitinib), a kinase inhibitor for the first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.

28 Sep 2018

Study suggests new target to treat prostate cancer

Hokkaido University researchers have uncovered a cellular protein that stabilizes a tumor promoting signaling pathway, suggesting a new target to treat prostate cancer.

22 Dec 2017

Osimertinib provides progression-free survival benefit to Asian patients with EGFR-mutated NSCLC

Osimertinib improves progression-free survival compared to standard first line therapy in Asian patients with EGFR-mutated non-small-cell lung cancer (NSCLC), according to the Asian subset analysis of the FLAURA trial presented at the ESMO Asia 2017 Congress, sumultaneously published in The New England Journal of Medicine.

20 Nov 2017

Researchers use gold nanoshells to effectively release cancer drugs inside tumors

Researchers investigating ways to deliver high doses of cancer-killing drugs inside tumors have shown they can use a laser and light-activated gold nanoparticles to remotely trigger the release of approved cancer drugs inside cancer cells in laboratory cultures.

8 Nov 2017